Thrombotic microangiopathy: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
*Associated with coexisting condition |
*Associated with coexisting condition |
||
**Autoimmune disease, including [[systemic lupus erythematosus]] or [[antiphospholid antibody syndrome]] |
**Autoimmune disease, including [[systemic lupus erythematosus]] or [[antiphospholid antibody syndrome]] |
||
** |
**[[Drug-induced thrombotic microangiopathy]], including [[quinine]], [[ticlopidine]], and [[chemotherapy]] ([[mitomycin]], [[gemcitabine]], [[cyclosporine]], and [[tacrolimus]], though it may also be caused by the underlying condition) |
||
**[[Sepsis]] and [[secondary hemolytic-uremic syndrome]] (usually from [[Streptococcus pneumoniae]] or [[influenza]]) |
|||
**[[Sepsis]] |
|||
**[[DIC]] |
**[[DIC]] |
||
**[[Malignancy]] |
**[[Malignancy]] |
||
Revision as of 13:51, 20 April 2023
- Syndrome of microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis leading to organ dysfunction
- Primary
- Associated with coexisting condition
- Autoimmune disease, including systemic lupus erythematosus or antiphospholid antibody syndrome
- Drug-induced thrombotic microangiopathy, including quinine, ticlopidine, and chemotherapy (mitomycin, gemcitabine, cyclosporine, and tacrolimus, though it may also be caused by the underlying condition)
- Sepsis and secondary hemolytic-uremic syndrome (usually from Streptococcus pneumoniae or influenza)
- DIC
- Malignancy
- HIV
